January Features
Announcements
|
PAR-15-085
Predictive Multiscale Models for Biomedical, Biological, Behavioral, Environmental and Clinical Research (U01)
Application due dates: March 9, 2015; May 29, 2015; September 29, 2015; January 29, 2016; May 30, 2016; September 29, 2016; January 30, 2017; May 29, 2017; and September 29, 2017
Expires: January 8, 2018
RFA-CA-15-002
Innovative Molecular Analysis Technologies for Cancer Research (R21)
Application due dates: March 17, 2015; June 17, 2015; and September 22, 2015.
Expires: September 23, 2015
RFA-CA-15-003
Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research (R33)
Application due dates: March 17, 2015; June 17, 2015; and September 22, 2015.
Expires: September 23, 2015
RFA-CA-15-004
Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)
Application due dates: March 17, 2015; June 17, 2015; and September 22, 2015.
Expires: September 23, 2015
RFA-CA-15-005
Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33)
Application due dates: March 17, 2015; June 17, 2015; and September 22, 2015.
Expires: September 23, 2015
PA-15-083
NIH Pathway to Independence Award (Parent K99/R00)
Application due dates: Standard dates apply
Expires: January 8, 2017
PAR-15-104
Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01)
Application due dates: April 1, 2015; July 8, 2015; November 10, 2015; March 11, 2016; July 8, 2016; November 10, 2016; and March 10, 2017
Expires: March 11, 2017
PAR-15-095
Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH2/UH3)
Application due dates: March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; and October 6, 2017
Expires: October 7, 2017
PAR-15-096
Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH3)
Application due dates: March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; and October 6, 2017
Expires: October 7, 2017
|
Large Budget Grant Applications (> $500,000)
NOT-OD-15-053Notice of NIH's Interest in Diversity Notice of Legislative Mandates in Effect for FY 2015
|
SERtalks: Causal Inference
February 6, 2015
Washington, D.C.
Translation of the Cancer Genome
February 7-9, 2015
San Francisco, CA
SeqSPACE Forum - Save the Date (topic to be announced)
March 3, 2015; 3:00 - 4:30 p.m. EST
American Society of Preventive Oncology
March 14-17, 2015
University of Alabama at Birmingham
American Association of Cancer Research Annual Meeting
April 18-22, 2015
Philadelphia, PA
Note: The AACR Molecular Epidemiology Working Group is accepting applications from molecular epidemiology consortia for meeting space during the Annual Meeting. Applications will be accepted through March 27, 2015. View announcement (third from top)
NIH Regional Seminar on Program Funding and Grants Administration
May 6-8, 2015
Baltimore, MD
Summer Curriculum for Cancer Prevention
July 6-31 and August 3-7, 2015
Bethesda, MD
Deadline for international applicants: February 15, 2015
Deadline for domestic (U.S.) applicants: March 15, 2015
|
|
EGRP encourages readers to submit items of interest to Cancer Epidemiology Matters E-News. EGRP reserves the right to decide whether or not materials are appropriate for inclusion.
|
The Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) funds research in human populations to understand the causes of cancer and related outcomes.
The Program fosters interdisciplinary collaborations, as well as the development and use of resources and technologies to advance cancer research and translation of this research, which serve as the basis for clinical and public health interventions.
|
|
 |
Each year, EGRP staff nominate and vote for manuscripts published by EGRP grantees that are deemed to have the greatest potential scientific and/or public health impact. The following publications were chosen for inclusion in the 2014 Research Highlights:
Breast Cancer
- Lange JM, Takashima JR, Peterson SM, Kalapurakal JA, Green DM, Breslow NE. Breast cancer in female survivors of Wilms tumor: a report from the National Wilms Tumor Late Effects Study. Cancer. 2014 Dec 1;120(23):3722-30.
- Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014 Aug 7;371(6):497-506.
- Fejerman L, Ahmadiyeh N, Hu D, Huntsman S, Beckman KB, Caswell JL, et al. Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. Nat Commun. 2014 Oct 20;5:5260.
- Sieh W, Rothstein JH, McGuire V, Whittemore AS. The role of genome sequencing in personalized breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2322-7.
- Kwan ML, John EM, Caan BJ, Lee VS, Bernstein L, Cheng I, et al. Obesity and mortality after breast cancer by race/ethnicity: the California Breast Cancer Survivorship Consortium. Am J Epidemiol. 2014 Jan 1;179(1):95-111.
Cervical CancerOvarian Cancer Skin Cancer
More details about the 2014 Research Highlights publications can be found on the EGRP website.
|
Funding Opportunities for Innovative Technologies to Prevent, Diagnose, and Treat Cancer 
What do the following scientific projects have in common?
All of the above projects were funded by NCI's Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) Programs.
The SBIR and STTR Programs at NIH are one of several funding sources for the development of technologies to aid cancer prevention, diagnosis, and treatment. SBIR and STTR Programs are a major source of early stage technology financing across Federal agencies in the United States. SBIR and STTR Programs are congressionally mandated and receive dedicated funding. Federal agencies such as NIH, with an extramural research and development (R&D) budget of more than $100 million, must set aside 2.9% of their budgets for the SBIR program, and those with a budget of more than $1 billion must set aside 0.4% of their budgets for the STTR program
The SBIR and STTR Programs both fund early stage R&D at small businesses; however, STTR requires that a small business (< 500 employees) formally collaborate with a research partner at a university or other non-profit research institution. SBIR requires that Principal Investigators (PIs) have their primary employment with a small business at the time of award and throughout the duration of the project, whereas primary employment with the STTR Program is not fixed. NCI's SBIR and STTR grant and contract mechanisms offer the opportunity for cancer epidemiologists to provide scientific and technical expertise to small business R&D in cancer prevention and diagnostic and treatment technologies. Cancer epidemiologists at academic institutions can participate in SBIR or STTR projects as co-PIs, co-investigators, or subcontractors.
SBIR and STTR Funding Mechanisms
The two types of SBIR and STTR funding opportunity announcements (FOAs) use the R43/44 or R41/42 grant mechanisms:
Each fiscal year, NCI also issues a solicitation for SBIR/STTR contract proposals. The deadline for fiscal year 2015 proposals has passed, but a new solicitation is likely in August 2015 for fiscal year 2016.
Scientists not already familiar with SBIR/STTR solicitations are likely to benefit from reviewing last fiscal year's program solicitation to become more familiar with the process and types of projects of interest to NCI. Examples of topics of interest to the Epidemiology and Genomics Research Program (EGRP) in NCI's Division of Cancer Control and Population Sciences include but are not limited to the following:
- Cancer biomarker discovery through multiplexing platforms to accurately measure low-abundance biomarkers;
- Integrated technological platforms for enabling multiplexed biomarker assays, including biosensors;
- Enrichment of stem cells for -omics analysis;
- Measuring environmentally toxic substances; and
- Detecting multiple infections in different populations.
Phases of SBIR and STTR Projects
SBIR and STTR programs are structured into three phases after funding has been awarded to a small business. Applications for awards are competitive and peer-reviewed.
- In Phase I, the awardee will be given $150,000 over a period of 6 months for SBIR, or $100,000 over a period of 1 year for STTR, to conduct a Proof-of-Concept study, meaning that the awardee must prove the technical merit and feasibility of the proposed R&D to receive further funding in Phase II.
- The objective in Phase II is to continue the R&D efforts begun in Phase I. SBIR/STTR Phase II awards generally do not exceed $1 million over a 2-year period. The Phase II Bridge Award enables previously funded SBIR Phase II awardees to continue their next stage of research by helping to address funding gaps that may occur between Phases II and III.
- In Phase III, awardees will pursue, with non-SBIR/STTR funding, the commercialization of their R&D activities from Phases I and II.
Resources and Contacts
The website for NCI's SBIR and STTR Programs provides tips for applying, answers to frequently asked questions, and examples of successful projects. NCI staff are available to offer advice to scientists interested in applying for funding through various grant and contract mechanisms to develop and/or implement innovative technologies for use in cancer prevention, diagnosis, and treatment.
For cancer epidemiology questions related to the SBIR and STTR Programs, contact Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, EGRP.
|
|
